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Objective: Osteoarthritis (OA) is one of the most prevalent musculoskeletal diseases. Collagen derivatives
are candidates for disease-modifying OA drugs. This group of derivatives can be divided into undena-
tured collagen (UC), gelatine and collagen hydrolysate (CH). Collagen derivatives are marketed as having
direct chondroprotective action and reducing complaints of OA. This review summarizes the evidence for
the effectiveness of symptomatic and chondroprotective treatment with collagen derivatives in patients
with OA.
Methods: Eligible randomised controlled trials (RCTs) and quasi-RCTs were identiﬁed by searching
PubMed, Embase and the Cochrane Central Register of Controlled Trials until November 2011. Method-
ological quality was assessed using methods of the Cochrane Back Review Group.
Results: Eight studies were identiﬁed: six on CH, two on gelatine, and one on UC. The pooled mean
difference based on three studies for pain reduction measured with the Western Ontario and McMaster
Universities Osteoarthritis (WOMAC) Index comparing CH with placebo was 0.49 (95% CI 1.10e0.12).
However, some studies report signiﬁcant between-group differences in pain when measured with
a visual analogical scale (VAS) or other instruments, or when CH is compared with glucosamine sulphate.
For disability no signiﬁcant between-group mean differences were found when comparing CH with
placebo. Gelatine compared with placebo and with alternative therapies was superior for the outcome
pain. UC compared with glucosamineþ chondroitin showed no signiﬁcant between-group differences
for pain and disability. The most reported adverse events of collagen derivatives were mild to moderate
gastro-intestinal complaints. The overall quality of evidence was moderate to very low.
Conclusions: There is insufﬁcient evidence to recommend the generalized use of CHs in daily practice for
the treatment of patients with OA. More independent high-quality studies are needed to conﬁrm the
therapeutic effects of collagen derivatives on OA complaints.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a chronic disease of the joint frequently
seen in knee, hip, spine and hand causing pain, stiffness, decreased
range of motion, and reduced quality of life. It is a serious health
problem reported to affect, for example, 27 million people in the
United States1.o: J.P.J. Van Vijven, Erasmus
ctice, Room Gk 1046, PO Box
. Van Vijven).
s Research Society International. PThe pathology of OA involves the whole joint in a disease
process that includes focal and progressive hyaline articular carti-
lage loss with concomitant changes in the bone underneath the
cartilage, including formation of osteophytes and bony sclerosis,
and changes in the synovium and joint capsule2.
OA is treated mainly by exercise (although only moderately
effective), combined with the use of analgesics (acetaminophen) or
non-steroidal anti-inﬂammatory drugs (NSAIDs)3. These medica-
tions are symptomatic but not disease modifying and have adverse
effects. During the last decades, disease-modifying osteoarthritis
drugs (DMOADs) have received increasing interest. These new
substances are aimed at preventing or diminishing the deteriora-
tion of joint tissue4. Collagen derivatives are candidate DMOADsublished by Elsevier Ltd. All rights reserved.
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collagen derivatives are based on the various degrees of hydrolysis
of collagen: undenatured collagen (UC), gelatine and collagen
hydrolysate (CH), with a molecular weight of 300 kDa, 20e90 kDa
and 2e9 kDa, respectively. CH is absorbed intestinally, as shown in
preclinical studies in mice. In plasma, it peaks at 6h after ingestion5.
In ‘gut-sac’ experiments, it was shown that gelatine is absorbed in
high molecular form (1e10 kD) to some extent, notwithstanding
the still widespread assumption that proteins are hydrolyzed in the
gastrointestinal tract prior to absorption, so that free amino acids
enter the circulation predominantly5. Administered in fermented
milk products, the plasma concentrations of CH increases6.
The various collagen derivatives are reported to have different
working mechanisms. UC is studied mainly in rheumatoid arthritis
(RA) patients and mostly collagen type II is used. It is thought to
have a working mechanism called oral tolerance, inducing
a reduction in autoimmune reactions against collagen of articular
cartilage, although not yet conclusively proven in human trials7.
Since OA is not an autoimmune disease, a potential effect needs to
be explained by a different workingmechanism, but this has not yet
been investigated.
CH and gelatine are thought to have the same working mech-
anism and differ only in bioavailability. Three possible mechanisms
of CH (and gelatine) can be proposed. Firstly, studies using oral
administration of radioactive-labelled gelatine in mice and in vitro
studies with CH, suggest that peptides can be used as building
blocks for the cartilage5,8,9. However, the data of these short-term
experiments of chondrocytes in monolayer were not conﬁrmed in
longer-term studies with chondrocytes in 3D constructs10,11. It is
not obvious whether the possible effects of CH are caused by the
special amino acid content (a relatively large amount of proline and
glycine) or by the effects of peptides that crossed the intestinal
mucosa.
Furthermore, bone changes play a role in the pathogenesis of
OA12. It is hypothesized that CH also inﬂuences bone metabo-
lism13,14. Finally, since chicken CH is reported to reduce blood
pressure in animals and humans, a possible working mechanism of
CH is via the vascular system15e17. This is plausible considering the
association between OA and atheromatous vascular disease of the
subchondral bone, as suggested by epidemiological studies18.
Collagen derivatives are heavily marketed in the lay press and
recommended to physicians, based on several randomised
controlled trials (RCTs). However, no independent high-quality
systematic review is yet available, which is needed to provide
evidence-based information for physicians and patients. Therefore,
this review summarizes the evidence from RCTs and quasi-RCTs
that have examined the effectiveness of collagen derivatives for
symptomatic and chondroprotective treatment in patients with OA.
Methods
Types of studies, participants, interventions and outcome measures
RCTs and quasi-RCTs were included that assessed the effec-
tiveness of oral intake of collagen derivatives (e.g., UC, gelatine or
CH) in patients with OA in any joint in whom the diagnosis was
based on clinical, or clinical and radiographic criteria. Preferably,
the following comparisons had been made: collagen derivatives vs
placebo, collagen derivatives vs no treatment, collagen derivatives
vs other pain medication (e.g., paracetamol or NSAIDs), one
collagen derivatives vs another collagen derivatives, and collagen
derivatives vs other DMOADs. Combined preparations of collagen
derivatives with other candidate DMOADs were excluded if the
collagen derivatives were not investigated solely in a separate
intervention group.The primary outcomes were pain severity, disability, and
adverse events. Secondary outcomes were chondroprotection,
quality of life, number of responders assessed with the
OMERACTeOARSI responder criteria 19, and health care consump-
tion. No restrictions were applied regarding the measuring
methods used for these outcomes, except for the outcome ‘number
of responders’ which has to meet the above-mentioned criteria.
Search methods
The following databases were searched: the Cochrane Central
Register of Controlled Trials (CENTRAL, The Cochrane Library, to
November 2011), PubMed (1966eNovember 2011), and EMBASE
(1988eNovember 2011). No language restrictions were applied.
Keywords used were osteoarthritis, degenerative arthritis, CH,
gelatine hydrolysate and type II collagen (Appendix 1).
In addition, the reference lists of the selected papers were
screened and trial registers were searched. Manufacturers of CH
were requested to provide us with any unpublished studies, and
experts in the ﬁeld were contacted and asked to complement our
list with any relevant references, abstracts and full-text articles.
Selection of studies
Two of the authors (JPJvV and SMAB-Z) independently exam-
ined article titles and abstracts for eligibility (Appendix 2). Then,
the full-text reports were screened to determine ﬁnal eligibility for
inclusion in the present review. Any disagreement was resolved by
consensus.
Data extraction
Two authors (JPJvV and PAJL) extracted data using a stand-
ardised data extraction form. Data were collected on methods,
duration of follow-up, participants and setting, interventions,
outcome measures and results.
Quality assessment
Two authors (JPJvV and APV) independently assessed the
methodological quality using the risk of bias form of the Cochrane
Back Review Group20. Disagreement was resolved by consensus.
A kappa statistic was calculated to assess the interobserver reli-
ability for judging the studies.
Two authors (JPJvV and PAJL) used the Grading of Recommen-
dations Assessment, Development and Evaluation (GRADE)
approach to evaluate the quality of evidence according to
outcome21.
Data synthesis
Continuous data are presented as (standardised) mean differ-
ences with 95% conﬁdence intervals (CI). Dichotomous data (e.g.,
occurrence of adverse effects and number of responders) are
expressed as relative risks (RR), odds ratios (OR), risk difference
(RD) or number needed to treat (NNT) with corresponding 95% CI.
Effect sizes are calculated using mean differences with their stan-
dard deviations (Cohen’s d).
RevMan analyses (RevMan5) were used to analyse the data. If
studies were sufﬁciently homogeneous concerning study pop-
ulation and intervention, the results of comparable groups were
pooled (if possible using a ﬁxed effect model). When statistical
heterogeneity measured with I2 was higher than 40%, a random
effects model was used.
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Where possible and relevant, subgroup analyses were made on
the effectiveness in the different joints (knee, hip, spine and hand)
as well as in different disease stages based on radiographic severity,
i.e., the KellgreneLawrence grading system of OA22.
A sensitivity analysis was performed on design characteristics,
eligibility criteria, data to be analysed and methods of analysis.
Results
Description of studies
A total of 1,336 references were found after the electronic
search (Fig. 1). In addition, 23 references were identiﬁed byRecords identified through
database searching
(n = 1336)
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Fig. 1. Flow diagram fosearching the reference lists of articles and via correspon-
dence. Finally, 24 full-text articles were examined and eight
studies were ﬁnally selected23e30. The kappa value for inter-
observer reliability for this selection was 0.75, which reﬂects
excellent agreement31. We searched trial registers and found
three trial protocols. We retrieved the associated study of one
protocol published on www.clinicaltrials.gov 26. On http://
apps.who.int/trialsearch we identiﬁed two protocols of
completed trials but we could not ﬁnd associated full-text
articles with our search strategy. No new clinical studies
were in progress.
Table I presents the characteristics of the eight included studies:
six were RCTs, one a quasi-RCT29, and one study had a cross-over
design23. A total of 1,187 participants were included: their mean
age was 57 years and 64.6% was female.dditional records identified
through other sources
(n = 23)
uplicates Records excluded
(n = 1324)
xt articles
 for eligibility
 = 24)
Full-text articles excluded
(n = 16)
Review (n = 8)
Non-OA population (n = 1)
Non-controlled trial (n = 2)
Combined preparations (n = 1)
Non-controlled trial and use of
combined preparations (n = 4)
 synthesis
sis (meta-analysis)
r study selection.
Table I
Characteristics of the included studies
Study and design Participants (n) Mean age
(years)
% female OA
location
OA
severity
Setting Interventions Outcomes Follow-up
Adam 1991
Cross-over trial
52 56 46.2 Knee or hip KL I-III US 1. collagen hydrolysate
2. gelatin 3. gelatinþ glycineþ
calcium hydrogen phosphate
4. chicken protein (placebo)
for 60 daysy
Several types of pain and
stiffness on a 3-point Likert scale.
Quality of life (total of
scores for pain and stiffness).
Concomitant medication.
9 weeks
Benito 2009 RCT 250 59 92.4 Knee KL I-III 6 study centres (Ecuador) 1. 10 g collagen hydrolysate
in pill form 2. a matching
amount of placebo for 6 month
Pain (VAS, WOMAC), stiffness
(WOMAC), disability (WOMAC),
quality of life (SF-36), responders
(decline 30 mm on VAS for pain),
adverse events.
26 weeks
Crowley 2009 RCT 52 59 42.3 Knee Moderate,
LFI 4.5e7.5
Two independent medical
research centres (Canada)
1. Undenatured collagen
type II (UC-II) 40 mg daily
in capsule form 2. 750 mg
glucosamine and 600 mg
chondroitin sulphate daily
for 90 days
Pain (VAS), WOMAC, disability
(Lequesne), adverse events,
concomitant medication.
13 weeks
McAlindon 2011 RCT 30 60 60 Knee Mild, KL II-III Single center (USA) 1. 10 g collagen hydrolysate
2. placebo for 48 weeks
dGEMRIC) T1 relaxation time,
T2 relaxation time, pain (WOMAC),
stiffness (WOMAC), function (WOMAC),
analgesic consumption, adverse events
48 weeks
McCarthy 2000 RCT 250 57 45.8 Knee ‘Mild’ An independent centre
for clinical and lifestyle
research (USA)
1. 10 grams collagen
hydrolysate, 300 mg calcium
carbonate and 60 mg ascorbic
acid 2. placebo for 14 weeks
Pain and stiffness (WOMAC, Lequesne,
Knee Pain Scale) and quality of life
(SF-36, Prolife Of Mood States)
14 weeks
Moskowitz 2000 RCT 389 US US Knee KL II-III 20 study centres
(UK, USA and Germany)
1. 10 g collagen hydrolysate
2. placebo for 24 weeks
Pain (WOMAC), stiffness (WOMAC),
disability (WOMAC), adverse events
(reported by participants)
32 weeks
Oberschelp 1985 CCT 64* 51 US Knee or hip US US 1. Gelatine 2. Gelatineþ
alternative therapies
(iontophoresis, medium
frequency electric
stimulation, etc.)
3. alternative therapies
only, for 12 weeks. z
Pain (unclear which measurement
instrument used), result of therapy
(4-point Likert scale).
12 weeks
Trc 2010 29 RCT 100 US US Knee Functional
class I-III
Four hospitals, further US 1. 10 g CH 2. Glucosamine
sulphate 1.5 g for 90 days
Pain (quadruple VAS), responders
pain (decline 20 mm on a
quadruple VAS), quality of life (SF-36),
concomitant medication, adverse events
12 weeks
KL: Kellgren and Lawrence Grading system. LFI: Lequesne Functional Index. US: unspeciﬁed. WOMAC: Western Ontario and McMaster Universities Osteoarthritis. : visual analogical scale.
* Only participants with OA and treated with either gelatine or alternative therapies were included in this review (n¼ 47).
y Gelatine þ calcium hydrogen phosphate is considered to be a gelatine compound and is not analysed as a separate substance.
z The intervention Gerontamin þ alternative therapy is not included in the analyses.
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examined patients with hip and knee OA 23, 29 OA severity wasmost
often deﬁned with Kellgren and Lawrence grade I-III23,24 or II-III26,
28.
Five of the eight studies assessed CH compared to placebo23,24,
26e28 or compared to glucosamine sulphate30. Two studies
assessed gelatine compared to placebo and to CH23 and compared
to alternative therapies29. One study assessed UC compared to
glucosamineþ chondroitin25.
All studies measured pain using several measurement instru-
ments: VAS24e25, 30, theWOMAC24, 26e28, a self-made 3-point Likert
scale23, and a not-speciﬁed instrument 29. Disability was measured
with the WOMAC24, 26e28 and the Lequesne Index 25, 27. Chon-
droprotective effects were measured with delayed Gadolinium
Enhanced MRI of Cartilage (dGEMRIC) and T2 mapping by one
study26. Adverse events were reported in six studies 24e26, 28e30
Methodological quality of included studies
The kappa value of the inter-observer reliability was 0.72 which
reﬂects good agreement31. There were serious limitations in the
methodological quality of all the studies (Table II). Only in three
trials was allocation adequately performed24e26. One trial was
considered to be quasi-randomised since contradictory terms were
used for allocation29. Allocation concealment was adequately per-
formed in only one study26. Two studies met the criteria for
blinding25,26. Several studies did not adequately address missing
outcome data24e28, 30.
Quality according to outcome
The quality per outcome was assessed according to the GRADE
approach (Appendix 3)21. The quality of evidence of all outcomes
was diminished because of methodological shortcomings
(Table III). In addition, the quality of evidence was reduced because
the results for most outcomes were imprecise in view of the low
number of included participants. Some comparators or outcome
measures were indirect, which is another criterion for diminished
quality of evidence. For example, Oberschelp made an indirect
comparison in choosing alternative therapies as a comparator29.Table II
Results of risk of bias assessment
Study Adequate
sequence
generation?
Allocation
concealment?
Blinding of:
- patient?
- care provider?
- outcome assessor?
Adam 1991 Unclear Unclear Unclear
Benito 2009 Yes Unclear* Unclear
Crowley 2009 Yes Uncleary Yes
McAlindon 2011 Yes Yes Yes
McCarthy 2000 Unclear Unclear Unclear
Moskowitz 2000 Unclear Unclear Unclear
Oberschelp 1985 Unclear Unclear Unclear
Trc 2010 Unclear Unclear Unclear
* Pre-sealed labelled envelopes were used, but it is unsure whether these were opaqu
y Computer-generated randomisation tables were used, but it was unclear whether an
z >15% drop-out and no Intention-To-Treat (ITT) analyses of the results of the main o
x No ITT-analysis on results of measurements after 30 days, although the drop-out rat
k >15% drop-out, 16 patients not included in the ITT analysis.
{ No ITT analysis although the drop-out rate was acceptable.
** A carry-over effect is suggested in the article and the (required) baseline measurem
yy A difference in the use of rescue medication was reported between the two treatme
zz Groups were not similar at baseline, with respect to the balancing of disease severitEffects of interventions
There were insufﬁcient trials per comparison (maximum of
three trials) to make funnel plots in order to visualize potential
publication bias.
The results for the various comparisons are summarized in
Table III.
1. Pain
Comparison of CH and placebo: three studies could be pooled
for pain measured with the WOMAC Index in a mean follow-up
period of six months24, 26, 28. A mean difference of 0.49 (95%
CI 1.10e0.12) was found in the pooled 610 participants, using
a ﬁxed effect model with I2¼ 9% (Fig. 2), which suits with an effect
size of 0.17. A negative mean difference in this case meant
a reduction in pain. This was consistent with the results of another
study (n¼ 190) that measured painwith the WOMAC but could not
be included in this meta-analysis because the data were not
reported27. However, this pooled effect was not consistent with
another small study (that also could not be included) that
measured the number of participants reporting several types of
pain before and after 60-days of therapy23. It was also not consis-
tent with the results of pain measurements with VAS24. In one
study, in subgroups of participants with severe radiographic OA,
signiﬁcant differences were found that were comparable with the
results in the whole study group of that study (Cohen’s d 0.4 for
differences in WOMAC scores)24.
When CH was compared to glucosamine sulphate during 90
days of treatment, signiﬁcant between-group differences were
found in favour of CHwhen painwas measured on a quadruple VAS
scale. When data were dichotomised with a cut-off value of
20 mm decrease on this quadruple VAS, a risk ratio of 1.84 (95% CI
1.20e2.82) was found in favour of CH30.
For several comparisons, no analysable data were shown for the
outcome pain. Adam reported to have found signiﬁcant between-
group difference for at least some types of pain (night pain, pain
at moving) when gelatine was compared with placebo23. Ober-
schelp reported a clear improvement in pain in the gelatine group
compared to the group receiving alternative therapies, but withoutIncomplete data
outcome addressed:
- drop-out
acceptable?
- Intention to
treat analysis?
Free of
selective
reporting?
Other bias:
- groups similar at baseline?
- co-interventions
avoided/similar?
- compliance acceptable?
- timing outcome
assessment similar?
Unclear Unclear No**
Noz Unclear Unclear
Nox Unclear Noyy
No{ Yes Nozz
Noz Unclear Unclear
Nok Unclear Unclear
Unclear Unclear Unclear
No{ Unclear Unclear
e and sequentially numbered.
independent person managed these tables
utcomes.
e was acceptable.
ents between each consecutive treatment were lacking.
nt groups, but it is unclear whether the difference was signiﬁcant.
y, measured with clinical outcome measures
Table III
Results and quality according to outcome
Comparison Outcome
Measuring instrument
No. of
studies
Quality No. of patients
intervention/
control
Effect Cohen’s d Comments
Absolute
difference (95% CI)
Relative
risk (95% CI)
CH vs placebo Pain
WOMAC, scale 0e20,
lower scores indicate less pain
4* Moderate 313/297 0.48 (1.04; 0.08) 0.17 Subgroup severe OA (n ¼ 128): mean
difference 1.30 (2.43; 0.17).
Pain
VAS, scale 0e100,
lower scores indicate less pain
1 Low 111/96 4.60 (8.89; 0.31) 0.30 Subgroup severe OA (n¼ 128): mean
difference 5.30 (10.47; 0.13)
Responders in pain
VAS, decline of 30 mm
1 Low 111/96 1.41 (1.13; 1.75)
Disability
WOMAC, scale 0e68,
lower scores indicate less disability
3 Moderate 313/297 0.74 (2.58; 1.09) 0.10
Chondroprotective effects
(dGEMRIC en T2 scores)
1 Low 15/15 After 24 weeks, some signiﬁcant
between-group differences were found,
which disapeared after 48 weeks
Adverse events CH
Counts of reported events
3 Moderate 313/297 Most mild to moderate gastrointestinal
complaints (nausea, ﬂatulence).
CH vs gelatine Pain
Several types of pain on
a 3-point Likert scale
1 Low 52/52 Not obvious whether reported scores
differ signiﬁcantly between groups.
CH vs glucosamine
sulphate
Pain (four types of pain
measured on a VAS)
1 Low 47/46 Signiﬁcant between-group differences
in favour of CH on all VAS scales.
Responders in painy
(20 mm decrease on
a quadruple VAS)
1 Low 47/46 1.84 (1.20; 2.82)
Adverse events CH
(counts of reported events)
1 Low 47/46 Mild gastrointestinal symptoms, no
signiﬁcant differences between groups.
Gelatine vs placebo Pain
Several types of pain on
a 3-point Likert scale
1 Low 52/52 Signiﬁcant between-group differences
for several types of pain.
Gelatine vs alternative
therapies
Pain
Not obvious what
instrument was used
1 Very low 25/22 Not obvious whether reported between-
group differences are signiﬁcant.
Adverse events of gelatine
Counts of reported events
1 Very low 25/22 Three patients with gastro-
intestinal symptoms.
UC vs glucosamine þ
chondroitin
Pain
Several types of pain,
VAS 0e100 mm
1 Low 26/26 Only ’percentages from baseline
values’ shown. No between-group
differences.
Disability
Lequesne Index
1 Low 26/26 Only ’percentages from baseline
values’ shown. No between-group
differences.
Adverse events UC
Counts of reported events
1 Low 26/26 35 adverse events in 16 patients,
mostly constipation and headache
CH: collagen hydrolysate. UC: undenatured collagen.
* Three of these studies are included in the meta-analysis.
y It is not clear whether this is calculated in mean VAS scores or whether it is 20 mm decrease on one of the four VAS scales.
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Fig. 2. Pain (WOMAC), CH vs placebo.
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the results29. Crowley et al. compared UC with glucosami-
neþ chondroitin and reported no between-group differences for
several types of pain 90 days from baseline measured with VAS25.
2. Disability
Comparison of CH and placebo resulted in three studies that
could be pooled in a ﬁxed effect model, with a total of 610
participants for a follow-up period of six months24, 26, 28. A mean
difference of 0.74 (95% CI 2.58e1.09) was found (Fig. 3), where
negative values indicate a reduction in disability. This corre-
sponds with an effect size of 0.10. This was consistent with
another study (n¼ 190 participants) using the WOMAC and the
Lequesne Index27. Further, UC was compared with glucosamine
and chondroitin and the authors reported no between-group
differences for pain and disability summary scores 90 days
from baseline, although some WOMAC items showed a signiﬁ-
cant difference25.
3. Adverse events
The proportion of patients with adverse events range from 13 to
87% with collagen derivative treatment and from 9 to 87% in the
control groups. For all collagen derivatives, most of the probably
and possibly related adverse events were mild to moderate
gastrointestinal complaints such as nausea, dyspepsia, diarrhoea
and ﬂatulence. In all trials, no signiﬁcant between-group differ-
ences were reported for the occurrence of adverse events.
None of the studies reported relevant signiﬁcant between-group
differences for secondary outcomes like joint stiffness, quality of
life and health care consumption. As regards chondroprotection,
there were signiﬁcant between-group differences in dGEMRIC
scores at two of the six locations in the knee (medial and lateral
tibia) that were measured after 24 weeks. However, these differ-
ences disapeared at 48 weeks follow-up26.
Subgroup and sensitivity analyses
No subgroup analyses could be made on effectiveness in the
different joints because data were not speciﬁed per joint, or in
different disease stages based on radiographic severity because
only one study investigated this subgroup.
No sensitivity analysis could be performed to compare studies
with high and low quality, since all studies were of moderate to low
quality.Fig. 3. Disability (WOMDiscussion
Key ﬁndings
There is no evident superiority of collagen derivatives over
placebo, or over other DMOADS, although this remains doubtful for
the outcome pain. The pooled mean difference between CH and
placebo for pain measured with the WOMAC was not signiﬁcant,
but there were signiﬁcant differences when pain was measured
with other instruments and when pain was measured in patients
with severe OA. It can be noted that the effect size for pain is 0.17,
which is in the same range as the effect size of acetaminophen3.
Despite low effect sizes acetaminophen is recommended in the
OARSI-recommendations for the management of hip and knee OA3.
However, there are much more studies on acetaminophen than on
CH and the quality of these studies is higher. The quality of evidence
for collagen derivatives is only moderate to very low. It can also be
noted that the included non-inferiority study that compares CH and
glucosamine sulphate shows that CH seems to reduce pain at least
as effective as glucosamine sulphate which is also recommended in
the above mentioned recommendations30, 3. However, since there
is still discussion about the effectivity of glucosamine and the
quality of this non-inferiority study is low, this is not a decisive
argument to recommend collagen derivatives.
Disability and secondary outcomes (such as joint stiffness and
quality of life) did not decrease to a greater extent in the collagen
derivatives group compared to placebo or to other DMOADs. A pilot
study could not give convincing evidence for chondroprotection
measured with MRI. Collagen derivatives seem to be safe and only
mild adverse events were reported. The risks of treatment are low
and the risk-beneﬁt ratio could therefore be in the advantage of the
beneﬁt if there was only a small positive effect. However, this
beneﬁt is not conclusively determined.
Strengths and limitations
This is the ﬁrst independently performed systematic review to
assess the efﬁcacy of the whole spectrum of collagen derivatives,
including only controlled trials (in any language), and with the
selection of studies, data extraction and assessment of methodo-
logical quality performed by two independent researchers.
Nevertheless, some limitations need to be addressed. Based on
the selection criteria of this review, only a few studies could be
included because most studies investigated various/differing
compounds and outcomes, implying that the body of evidence is
small for most compounds. Moreover, based on the GRADEAC), CH vs placebo.
J.P.J. Van Vijven et al. / Osteoarthritis and Cartilage 20 (2012) 809e821816approach, the quality of the evidence is moderate to very low
(Table III). In all studies there were limitations in the methodology,
most of the results were imprecisely presented, and some
comparisons or outcomes were indirect ones.
Secondly, it should be noted that four of the trials were funded
by manufacturers or traders of the investigated substance24e26, 28.
In the remaining four studies, no funding source was speciﬁed, but
a conﬂict of interest cannot be excluded.
Thirdly, most studies were performed for knee OA, whichmeans
that no evidence-based statements about hip, spine and hand OA
can be reported. Moreover, some comparisons that are important to
evaluate the efﬁcacy of collagen derivatives were not investigated,
e.g., a comparison between UC and placebo. Additionally, some
outcomes were sparsely investigated (e.g., chondroprotection that
was only investigated in a pilot study). Some outcome measures
were assessed by using self-made non-standardized measuring
instruments, and for several outcomes no data were reported or
were described in an inconclusive way. For example, this occurred
several times in the two studies investigating gelatine23, 29.
The most likely bias in the present review is that of publication
bias. Becausewe included (n¼ 8) less than ten studies in our review
we refrained from tests for funnel plot asymmetry32. We attempted
to minimize this bias as far as possible by searching in ‘grey’ liter-
ature, searching in reference lists, and by contacting several
manufacturers and experts in the ﬁeld. However, because collagen
derivatives (especially CH) are heavily marketed and most research
is initiated by the manufacturers of collagen derivatives, the
possibility of unpublished studies remains.Comparison with other studies or reviews
We identiﬁed 8 studies that examined the clinical effects of
collagen derivatives in the last 10 years 33e40. However, we found
no reviews on the effectiveness of UC.
Two systematic reviews discussed CH in the context of nutra-
ceuticals and include respectively two and three trials33, 38. It is
concluded that there is lack of evidence for efﬁcacy. Shortcomings
of both systematic reviews are the limited number of included
studies, the restricted analysis and discussion of studies on CH and
that they are not independent given the funding source and the
connections of the authors. The conclusion of these reviews is
consistent with that of a non-systematic review39.
The remaining non-systematic reviews concluded that clinical
trials ‘suggest’ or ‘demonstrate’ that CH may provide symptomatic
relief for some patients with OA. The review of Clayton relies on
only one clinical trial36, while Kasper includes only three trials,
both controlled and non-controlled40. The studies of Flechsenhar
and Bello et al. reported the available evidence on CH including six
and seven studies, respectively34, 37. However, they also included
non-controlled trials and not all included trials were performed in
an OA population (i.e., they also investigated athletes and patients
with chondropathia patellae). Moreover, these studies were not
independently performed as they were funded by the manufac-
turers of CH. It can be concluded that the results of our review are
consistent with the results of the above-mentioned systematic
reviews, but not with most non-systematic reviews.Conclusion
The results presented here show a dubious effect of CH, gelatine
and UC on pain; however, there was considerable heterogeneity
between the included studies. The evidence of most outcomes was
of moderate to low quality. Collagen derivatives seem to be safe
since only mild adverse events were reported.We conclude that there is insufﬁcient evidence to recommend
the generalized use of CHs in daily practice for the treatment of
patients with OA.
More independent and high-quality studies are needed to
establish the therapeutic effects of collagen derivatives and to
conﬁrmwhether or not they are chondroprotective. In addition, the
use of standardised and validated measuring instruments is
strongly recommended.
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Appendix 1. Search strategy
#1 osteoarthrit*[tw]
#2 degenerative arthrit*[tw]
#3 #1 OR #2
#4 collagen*[tw] OR gelatin*[tw]
#5 hydroly*[tw]
#6 collagen type II[tw] OR type II collagen[tw] OR collagen
type 2 [tw] OR type 2 collagen [tw]
#7 #4 AND (#5 OR #6)
#8 animals [mh] NOT humans [mh]
#10 #7 NOT #8
Pubmed
osteoarthrit*[tw] OR degenerative arthrit*[tw]) AND ((collagen*
[tw] OR gelatin*[tw]) AND hydroly*[tw] OR (collagen type ii[tw] OR
type ii collagen[tw] OR collagen type 2[tw] OR type 2 collagen[tw])
NOT (animals[mesh] NOT humans[Mesh])
Embase
osteoarthrit* OR degenerative NEAR/2 arthrit* AND ((collagen*
OR gelatin*) NEAR/2 hydroly* OR collagen NEAR/2 (’type ii’ OR
’type 2’)) NOT ([animals]/lim NOT [humans]/lim)
Central
*(osteoarthrit* OR degenerative arthrit*) AND ((collagen* OR
gelatin*) NEAR/2 hydroly*OR collagenNEAR/2 (’type ii’OR ’type 2’))
Appendix 2. Eligibility criteria for selection of studies
1. Types of studies
Description of study design ﬁtting a Randomized controlled trial
 Quasi-randomized trial
 Clinical controlled trial
J.P.J. Van Vijven et al. / Osteoarthritis and Cartilage 20 (2012) 809e821 817 Cross-over trial
2. Types of participants
Patients with osteoarthritis Established by clinical or radiological methods (or according to
the ACR criteria)
 Established/diagnosed by a physician
3. Types of interventions
Oral intake of
 Collagen hydrolysateAppendix 3. Quality and results according to outcome.
Table 1
Quality per outcome according to the GRADE approach
Comparison Outcome No.
of
studies
De
Lim
in
CH vs placebo Pain (WOMAC, scale 0e20,
lower scores indicate less pain)
4y Se
Pain (VAS, scale 0e100, lower
scores indicate less pain)
1 Se
Responders in pain
(VAS, decline of 30 mm)
1 Se
Disability (WOMAC, scale 0e68, lower
scores indicate less disability)
3 Se
Joint stiffness (WOMAC, scale 0e8,
lower scores indicate less joint stiffness)
3y Se
Quality of life (several scales) 3 Se
Health care consumption (use of analgesics) 1 Se
Chondroprotective effects
(dGEMRIC en T2 scores)
1 Se
Adverse events CH (counts of reported events) 3 Se
CH vs gelatine Pain (several types of pain measured
on a 3-point Likert scale)
1 Se
Joint stiffness (several types of stiffness
measured on a 3-point Likert scale)
1 Se
Quality of life (sum of several pain,
stiffness and sensitivity scores)
1 Se
Health care consumption (use of analgesics) 1 Se
CH vs glucosamine
sulphate
Pain (four types of pain measured on a
VAS 0e100 mm, lower scores
indicate less pain)
1 Se
Responders in pain* (20 mm decrease
on a quadruple VAS, lower scores
indicate less pain)
1 Se
Quality of life (SF-36, higher scores indicate
better health-related quality of life)
1 Se
Health care consumption (use of analgesics,
number of tablets per day)
1 Se
Adverse events (counts of reported events) 1 Se
Gelatine vs placebo Pain (several types of pain measured on a
3-point Likert scale, dichotomous)
1 Se
Joint stiffness (several types of stiffness
measured, dichotomous)
1 Se
Quality of life (sum of several pain and
stiffness scores, lower scores indicate
better quality of life)
1 Se
Health care consumption (use of analgesics) 1 Se
Gelatine vs alternative
therapies
Pain (not clear what measuring
instrument was used)
1 Se
Result of therapy (4-point Likert scale, cut-off
between no result and moderate result)
1 Se
Adverse events of gelatine
(counts of reported events)
1 Se Hydrolyzed collagen
 Degraded collagen
 Denatured collagen
 Gelatin
 Gelatin hydrolysate
 Hydrolyzed gelatine
 Collagen peptide
 Undenatured collagen
 Collagen
Combination of all three items requiredcrease in quality of evidence Increase in
quality of
evidence
itations
design
Inconsistency Indirectness Imprecision{ Publication
bias
rious Noz No No Unlikely No
rious No No Serious Unlikely No
rious No No Serious Unlikely No
rious No No No Unlikely No
rious No No No** Unlikely No
rious Noz No No** Unlikely No
rious No No Serious Unlikely No
rious No No Serious Unlikely No
rious No No No Unlikely No
rious No No Serious Unlikely No
rious No No Serious Unlikely No
rious No Seriousx Serious Unlikely No
rious No No Serious Unlikely No
rious No No Serious Unlikely No
rious No No Serious Unlikely No
rious No No Serious Unlikely No
rious No No Serious Unlikely No
rious No No Serious Unlikely No
rious No No Serious Unlikely No
rious No No Serious Unlikely No
rious No Seriousx Serious Unlikely No
rious No No Serious Unlikely No
rious No Seriousk Serious Unlikely No
rious No Seriousk Serious Unlikely No
rious No Seriousk Serious Unlikely No
(continued on next page)
Table 1 (continued )
Comparison Outcome No.
of
studies
Decrease in quality of evidence Increase in
quality of
evidence
Limitations
in design
Inconsistency Indirectness Imprecision{ Publication
bias
UC vs glucosamineþ
chondroitin
Pain (several types of pain, VAS 0e100 mm,
lower scores indicate less pain)
1 Serious No No Serious Unlikely No
Disability (Lequesne Index, scale 0e24,
lower scores indicate less disability)
1 Serious No No Serious Unlikely No
Health care consumption
(use of rescue medication)
1 Serious No No Serious Unlikely No
Adverse events UC (counts of reported events) 1 Serious No No Serious Unlikely No
CH: collagen hydrolysate. UC: undenatured collagen.
* It is not obvious whether this is calculated in mean VAS scores or that it is  20 mm decrease on one of the four VAS scales.
y Not all studies are included in the meta-analysis
z The results of the study of Adam et al. were not consistent with the results of the other studies on this outcome. However, the degree of inconsistency cannot be
demonstrated because Adam et al. did not report absolute mean differences.
x Measures for pain, stiffness and sensitivity for cold and weather are summed. This is an indirect measure for quality of life
k Alternative therapies’ is an indirect comparator because it can not be rated among placebo, DMOADs or standard therapy of OA.
{ Threshold rule-of-thumb values were used to assess imprecision. For dichotomous outcomes, imprecision was supposed when total number of events was less than 300,
for continuous outcomes when total population size was less than 400.
** Although not all studies could be pooled in a meta-analysis, narrative conclusions can be drawn over > 400 participants.
Table 1
Quality per outcome according to the GRADE approach (continued)
Comparison Outcome Quality Importance * No. of patients
intervention/
control
Effect Cohens’ D
(percent
change)
Comments
Absolute
difference
(95% CI)
Relative
risk (95% CI)
CH vs placebo Pain (WOMAC, scale 0e20,
lower scores indicate less pain )
Moderate 8 313/297 0.48
(1.04; 0.08)
0.17 (22) Subgroup severe
OA (KL grade III,
n¼ 128): mean
difference 1.30
[2.43; 0.17].
Pain (VAS, scale 0e100,
lower scores indicate less pain)
Low 8 111/96 4.60
(8.89; 0.31)
0.30 (16) Subgroup severe
OA (KL grade III,
n¼ 128): mean
difference 5.30
[10.47; 0.13]
Responders in pain
(VAS, decline of 30 mm)
Low 8 111/96 1.41
(1.13; 1.75)
Disability (WOMAC, scale 0e68,
lower scores indicate
less disability)
Moderate 8 313/297 0.74
(2.58; 1.09)
0.10 (14)
Joint stiffness (WOMAC,
scale 0e8, lower scores
indicate less joint stiffness)
Moderate 6 126/111 0.08
(0.60; 0.45)
0.05 (7) McCarthy et al.
reported to have not
found signiﬁcant
between-group
differences for stiffness
(WOMAC)
Quality of life (several scales) Moderate 8 250/250 Two studies reported
no signiﬁcant mean
differences (SF-36),
unlike Adam who used
a self-made instrument.
Health care consumption
(use of analgesics)
Low 6 52/52 Adam reports a
between-group difference,
not obvious whether
signiﬁcant.
Chondroprotective effects
(dGEMRIC en T2 scores)
Low 6 15/15 After 24 weeks, some
signiﬁcant between-
group differences were
found, which disapeared
after 48 weeks
Adverse events CH (counts of
reported events)
Moderate 8 313/297 Most mild to moderate
gastrointestinal
complaints like nausea
and ﬂatulence.
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Table 1 (continued )
Comparison Outcome Quality Importance * No. of patients
intervention/
control
Effect Cohens’ D
(percent
change)
Comments
Absolute
difference
(95% CI)
Relative
risk (95% CI)
CH vs gelatine Pain (several types of pain
measured on a 3-point
Likert scale)
Low 8 52/52 Not obvious whether
reported scores differ
signiﬁcant between
groups.
Joint stiffness (several types
of stiffness measured on a
3-point Likert scale)
Low 6 52/52 Not obvious whether
reported scores differ
signiﬁcant between
groups.
Quality of life (sum of several pain,
stiffness and sensitivity scores)
Very low 8 52/52 Not obvious whether
reported scores differ
signiﬁcant between
groups.
Health care consumption
(use of analgesics)
Low 6 52/52 Not obvious whether
reported between-group
differences are signiﬁcant.
CH vs glucosamine
sulphate
Pain (four types of pain
measured on a VAS 0e100 mm,
lower scores indicate less pain)
Low 8 47/46 Signiﬁcant between-
group differences in
favour of CH on all
VAS scales.
Responders in paink
(20 mm decrease
on a quadruple VAS, better
indicates by less)
Low 8 47/46 1.84
(1.20; 2.82)
Quality of life, physical summary
(SF-36, higher scores indicate
better health-related quality of life)
Low 8 46/40 1.80
(2.03; 5.63)
0.20 (43) Changes in some of
the 8 scales were
signiﬁcant different
between two groups.
Quality of life, mental summary
(SF-36, higher scores indicate better
health-related quality of life)
Low 8 46/40 1.30
(1.95, 4.55)
0.17 (186) Changes in some
of the 8 scales were
signiﬁcant different
between two groups.
Health care consumption
(use of analgesics,
number of tablets per day)
Low 6 47/46 0.10
(0.04; 0.24)
0.29 (50)
Adverse events CH
(counts of reported events)
Low 8 47/46 Mild gastrointestinal
symptoms, no
statistically signiﬁcant
differences in incidence
(4.3% vs 10.6%,
respectively)
Gelatine vs
placebo
Pain (several types of pain
measured on a 3-point Likert
scale, dichotomous)
Low 8 52/52 Signiﬁcant between-
group differences for
several types of pain.
Joint stiffness (several types
of stiffness measured,
dichotomous)
Low 6 52/52 Not obvious whether
reported scores differ
signiﬁcant between
groups.
Quality of life (sum of several
pain and stiffness scores,
lower scores indicate better
quality of life)
Very low 8 52/52 Signiﬁcant more
decrease of sum of
scores in gelatine-group.
Health care consumption
(use of analgesics)
Low 6 52/52 Not obvious whether
reported between-group
differences are signiﬁcant.
Gelatine vs
alternative
therapies
Pain (not obvious what
measuring instrument was used)
Very low 8 25/22 Not obvious whether
reported between-group
differences are signiﬁcant.
Result of therapy
(4-point Likert scale,
cut-off between no result
and moderate result)
Very low 6 25/22 2.25
(1.34; 3.77)
Adverse events of gelatine
(counts of reported events)
Very low 8 25/22 Three patients with
gastro-intestinal
symptoms.
(continued on next page)
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Table 1 (continued )
Comparison Outcome Quality Importance * No. of patients
intervention/
control
Effect Cohens’ D
(percent
change)
Comments
Absolute
difference
(95% CI)
Relative
risk (95% CI)
UC vs
glucosamineþ
chondroitin
Pain (several types of pain,
VAS 0-100 mm,
lower scores indicate less pain)
Low 8 26/26 Only ’percentages from
baseline values’ shown.
No between-group
differences.
Disability (Lequesne
Index, scale 0e24,
lower scores indicate
less disability)
Low 8 26/26 Only ’percentages from
baseline values’ shown.
No between-group
differences.
Health care consumption
(use of rescue medication)
Low 6 26/26 Between-group
difference in use of
rescue medication
(more in Gþ C group).
Not obvious whether
signiﬁcant.
Adverse events UC
(counts of reported events
Low 8 26/26 35 AE in 16 patients,
mostly constipation
and headache, 4 possibly
related.
CH: collagen hydrolysate. UC: undenatured collagen
*Level of importance: 1e3¼ no importance, 4e6¼ important, 7e9¼ critical
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